The United States’ Drug Enforcement Agency (“DEA”) has given a Schedule II classification to Insys Therapeutics’ medication Syndros – a […]
The United States’ Drug Enforcement Agency (“DEA”) has given a Schedule II classification to Insys Therapeutics’ medication Syndros – a […]